Advertisement
U.S. markets open in 5 hours 27 minutes

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
40.37-0.49 (-1.20%)
At close: 04:00PM EDT
40.37 0.00 (0.00%)
After hours: 05:39PM EDT

Halozyme Therapeutics, Inc.

12390 El Camino Real
San Diego, CA 92130
United States
858 794 8889
https://halozyme.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees373

Key Executives

NameTitlePayExercisedYear Born
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.President, CEO & Director1.45M2.47M1963
Ms. Nicole LaBrosseSenior VP & CFO727.04kN/A1983
Dr. Michael J. LaBarre Ph.D.Senior VP & Chief Technical Officer723.24kN/A1964
Ms. Cortney Caudill M.B.A.Chief Operations OfficerN/AN/AN/A
Ms. Tram BuiHead of Investor Relations & Corporate CommunicationsN/AN/AN/A
Ms. Amy Marinne FoxChief Human Resources OfficerN/AN/AN/A
Dr. Steve Knowles MBBSChief Medical OfficerN/AN/AN/A
Dr. Christopher Bryant Ph.D.Chief Manufacturing Officer & Head of Technical OperationsN/AN/A1961
Ms. Kristin SchwartzbauerHead of QualityN/AN/AN/A
Mr. Gary GroteChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Halozyme Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 2. The pillar scores are Audit: 4; Board: 1; Shareholder Rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.